Risk of Cancer byATMMissense Mutations in the General Population
- 20 June 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (18) , 3057-3062
Abstract
Purpose: Truncating and missense mutations in the ATM gene, which cause insufficient DNA damage surveillance, allow damaged cells to proceed into mitosis, which eventually results in increased cancer susceptibility. We tested the hypotheses that ATM Ser49Cys and ATM Ser707Pro heterozygosity increase the risk of cancer overall, of breast cancer, and of 26 other cancer subtypes in the general population.Patients and Methods: We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years, during which 2,056 developed cancer.Results: Multifactorially adjusted hazard ratios for ATM Ser49Cys heterozygotes versus noncarriers were 1.2 (95% CI, 0.9 to 1.5) for cancer overall, 0.8 (95% CI, 0.3 to 2.0) for breast cancer, 4.8 (95% CI, 2.2 to 11) for melanoma, 2.3 (95% CI, 1.1 to 5.0) for prostate cancer, and 3.4 (95% CI, 1.1 to 11) for cancer of the oral cavity/pharynx. Multifactorially adjusted hazard ratios for ATM Ser707Pro heterozygotes versus noncarriers were 0.8 (95% CI, 0.6 to 1.2) for cancer overall, 0.6 (95% CI, 0.2 to 1.6) for breast cancer, 10 (95% CI, 1.1 to 93) for thyroid/other endocrine tumors, and 2.7 (95% CI, 1.0 to 7.6) for cancer of corpus uteri.Conclusion: ATM missense mutations do not increase the risk of cancer overall or of breast cancer in the general population; however, we observed in exploratory analyses that ATM missense mutations may be associated with an increased risk of other cancer subtypes. As we did multiple comparisons, some of these findings could represent chance findings rather than real phenomena.Keywords
This publication has 21 references indexed in Scilit:
- A common coding variant in CASP8 is associated with breast cancer riskNature Genetics, 2007
- The ATM-mediated DNA-damage response: taking shapeTrends in Biochemical Sciences, 2006
- TheATMmissense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancerHuman Mutation, 2006
- Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer riskHuman Molecular Genetics, 2006
- Cancer Risks and Mortality in Heterozygous ATM Mutation CarriersJNCI: Journal of the National Cancer Institute, 2005
- ATM polymorphisms as risk factors for prostate cancer developmentBritish Journal of Cancer, 2004
- ATM and Genome Maintenance: Defining Its Role in Breast Cancer SusceptibilityJournal of Mammary Gland Biology and Neoplasia, 2004
- A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controlsCancer, 2004
- Cancer Risk in ATM Heterozygotes: A Model of Phenotypic and Mechanistic Differences between Missense and Truncating MutationsMolecular Genetics and Metabolism, 1999
- Incidence of Cancer in 161 Families Affected by Ataxia–TelangiectasiaNew England Journal of Medicine, 1991